Form 4: Sutro Biopharma Director Granted Stock Options

Sutro Biopharma director Michael Dybbs was granted 1,500 stock options with an exercise price of $10.38, vesting monthly starting January 23, 2026.

Summary

• Michael Dybbs, a director at Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
• The options have an exercise price of $10.38 per share.
• The options will vest monthly at a rate of 16.67% of the total award, contingent on Dybbs' continued service.
• The first vesting tranche is scheduled for January 23, 2026.
• The options expire on December 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with the company's long-term performance.

Positives

• The grant of 1,500 stock options to Director Michael Dybbs aligns his interests with long-term shareholder value.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The options are subject to a monthly vesting schedule over approximately six months, with the first tranche vesting on January 23, 2026, contingent on continued service. This implies an expectation of continued engagement from the director.

Industry Context

Granting stock options to directors is a standard practice in the biotechnology industry, and publicly traded companies in general, to align the interests of board members with those of shareholders and to incentivize long-term commitment and performance.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of equity compensation, consistent with corporate governance practices across the biotechnology sector and broader public markets.
• The vesting schedule is typical for incentivizing continued service.

Corporate Governance

Related Party Transactions

• Grant of 1,500 stock options to Michael Dybbs, a director of Sutro Biopharma, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential dilution upon exercise of options, but also potential for increased director alignment with shareholder interests.

Next Steps

• Continued vesting of the stock options monthly, with the first tranche on January 23, 2026.
• Potential exercise of options by Michael Dybbs in the future, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. It does not contain information that would fundamentally alter the investment thesis for Sutro Biopharma, Inc. While it aligns the director's interests with long-term shareholder value, it's a standard event and not indicative of a significant change in company prospects or valuation. Therefore, a "Hold" recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.

Keywords

Sutro Biopharma, STRO, Michael Dybbs, stock options, director, insider transaction, equity compensation